Enanta Pharmaceuticals (NASDAQ:ENTA) will be announcing its earnings results after the market closes on Monday, November 26th. Analysts expect the company to announce earnings of $1.21 per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.
ENTA opened at $78.99 on Friday. Enanta Pharmaceuticals has a 12 month low of $46.86 and a 12 month high of $127.77. The firm has a market cap of $1.53 billion, a P/E ratio of 86.80 and a beta of 1.04.
Several research analysts recently commented on ENTA shares. BidaskClub raised Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday. ValuEngine cut Enanta Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 8th. Zacks Investment Research cut Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, November 8th. JMP Securities reissued a “buy” rating and set a $120.00 target price on shares of Enanta Pharmaceuticals in a research note on Tuesday, July 31st. Finally, UBS Group cut Enanta Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 8th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $104.00.
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus.
Further Reading: Can systematic risk be avoided?
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.